WHO vaccine-preventable diseases: monitoring system. 2019 global summary

Last updated 15-July-2019 (data as of 1-July-2019)
Next overall update Winter 2019
EPI mother and child logo         
Select a country

Development status: Developing GNI / capita (US$): 1 Infant (under 12 months) mortality rate: 262
GDP / capita (US$): 1 Child (under 5 years) mortality rate: 312

Population data in thousands3

  2018  2017  2016  2015  2014  2000  1990  1980 
Total population 28'887  29'402  29'851  30'082  30'043  24'192  19'633  15'183 
Births 524  535  546  558  569  576  563  496 
Surviving infants 511  522  534  547  559  566  549  478 
Pop. less than 5 years 2'545  2'699  2'820  2'873  2'942  2'791  2'701  2'291 
Pop. less than 15 years 7'992  8'224  8'423  8'537  8'643  8'219  7'438  6'257 
Female 15-49 years 14'770  15'171  15'548  15'825  15'832  12'741  9'934  7'331 

Number of reported cases

(Click for retrospective incidence data for Venezuela (Bolivarian Republic of))
Diphtheria
ChartChart
  775  786  31  31 
Japanese encephalitis
 
Measles
ChartChart ChartChart
  5'667  727  22  9'881  9'750 
Mumps
ChartChart
  81  50  156  69  5'851 
Pertussis
ChartChart
  144  21  555  1'389  3'247 
Polio*
  11 
Rubella
ChartChart
  13'927 
Rubella (CRS)
ChartChart
 
Tetanus (neonatal)
ChartChart
  28  129 
Tetanus (total)**
ChartChart
  11  16  23  14  12  27  99  476 
Yellow fever
ChartChart
 
* Polio refers to all polio cases (indigenous or imported), including polio cases caused by vaccine derived polio viruses (VDPV). For disaggregated data please click on this hyperlink: https://extranet.who.int/polis/public/CaseCount.aspx
it does not include cases of vaccine-associated paralytic polio (VAPP) and cases of non polio acute flaccid paralysis [AFP]).
** Neonatal Tetanus and Total Tetanus cases equality may be the result from a lack of non-Neonatal Tetanus surveillance system.

Percentage target population vaccinated by antigen

Hovering over an antigen reveals its fuller definition
  Most recent coverage survey4  

Official country estimates5

  (Click for retrospective coverage estimates data for Venezuela (Bolivarian Republic of))
Vaccine year result method % card seen                                                
BCG 1999  90  MICS     92  99*  99*  99  95  99  82  72 
DTP1 1999  88  MICS     84  95  99*  98  88  92 
DTP3 1999  59  MICS     60  66  84  87  78  77  63  56 
IPV1          32  70  68 
HepB_BD          55  74  56  89  82  14 
HepB3          60  66  84  87  78 
Hib3          60  66  84  87  78 
JapEnc         
MCV1          74  96  88  92  89  84  62  50 
MCV2          39  59  53  52  50 
MenA         
PCV1          19  78 
PCV2          14  63 
PCV3          24 
Pol3 1999  40  MICS     53  79  82  87  79  86  72  95 
Rota1          21  67  90  81 
RotaC          18  47  84  76 
RCV1          74  96  88  92  89 
TT2plus          32  43  45  52  34 
PAB         
VAD1         
YFV          35  83  84  85  82  17 
* indicates the country reported above 100% coverage.

  Next update: Mid July 2020

WHO-UNICEF estimates6

  (Click for full retrospective WHO-UNICEF coverage estimates data for Venezuela (Bolivarian Republic of))
BCG
ChartChart
  92  94  97  99  97  99  82  72 
DTP1
ChartChart
  84  95  97  98  88  92  84  79 
DTP3
ChartChart
  60  66  84  87  78  77  63  56 
HepB3
ChartChart
  60  66  84  87  78 
HepB_BD
ChartChart
  55  56  56  64  72  14 
Hib3
ChartChart
  60  66  84  87  78 
IPV1
  32  70  68 
MCV1
ChartChart
  74  96  88  92  89  84  61  50 
MCV2
ChartChart
  39  59  53  52  50 
PCV3
ChartChart
  24 
Pol3
ChartChart
  53  79  82  87  79  86  72  95 
RCV1
ChartChart
  74  96  88  92  89  84 
RotaC
ChartChart
  18  47  84  76 
YFV
ChartChart
  35  83  84  85  82  17 

Click to download WHO-UNICEF coverage estimates data for PAB time series.
Click to download WHO-UNICEF coverage estimates data for HPV time series.

Number of districts in the country 335  Proportion of
districts reporting
DTP3 coverage:
% of coverage reports received at national
level vs number of reports expected
97 
   
/
|
|
\
Greater or equal to 90% 25
From 80 to 89% 9
From 50 to 79% 41
Less than 50% 25
Proportion of districts
not reporting DTP3 coverage
0
DTP3 reported coverageDTP3 reported coverage

Immunization Schedule (2018 or latest available)

Hovering over an antigen reveals its fuller definition
Vaccine Schedule Entire country Comment
BCG birth; Yes
DTwPHibHepB 2, 4, 6, 18 months; 5 years; Yes
HepB_Adult 1st contact; +1, +6 months; Yes risk groups: pregnant women, health personnel, sex workers, dialysis patients
HepB_Pediatric birth; Yes
Influenza_Adult >60 years; Yes and adults with chronic conditions, pregnant women, healthcare workers
Influenza_Pediatric 6-23 months; Yes and children with chronic conditions
IPV 2 months; Yes
MenBC 1st contact, +2 months; Yes outbreaks and risk groups
MMR 12, 18 months; Yes and 1 dose to international travellers
OPV 4, 6, 18 months; 5 years; Yes
Pneumo_conj 2, 4, 12 months; Yes
Pneumo_ps >60 years; + 5 years; Yes
Rabies 1st contact; +3, +7, +14, +28 days; Yes post-exposure by contact with probably infected animals, prophylaxis of health workers
Rotavirus 2, 4 months; Yes
Td 1st contact; +1, +6 months; +1, +1 year; Yes Y10 at school, CBAW, pregnant women, health personnel, chronic sick, elderly, other risk groups
YF 1 year; Yes and international travellers and boarder areas

Immunizaton indicators

Indicator Expected answer 2018  2017  2016  2015  2014  2013  2012 

Planning and management

Has the country a Multi-Year Plan (MYP) for immunization? Yes/No/NR No  No  No  Yes  Yes  Yes  Yes 
What years does the MYP cover? number NA  NA    2014-2018  2015-2020  2013-2018   
Nº of districts with microplans that include activities to raise immunization coverage number        

System performance

Total Nº districts in country number 335  335  335  335  335  335  335 
Nº districts with DTP3 coverage >=80% number 113  134  256  247  192  178  188 
% of districts with DTP3 coverage >=80% From 0 to 100% 34  40  76  74  57  53  56 
Nº districts with measles (MCV1) coverage >=95% number 94  210  172  169  164  91  103 
% of districts with MCV1 coverage >=95% From 0 to 100% 28  63  51  50  49  27  31 

Safety

Has the country a vaccine adverse events review committee? Yes/No/NR/ND No  No  No  Yes  Yes  Yes  No 
Is there a national system to monitor adverse events following immunization (AEFI)? Yes/No/NR Yes  Yes  Yes  Yes  Yes  Yes  Yes 

Finance

% of Immunization expenditure financed, using Government funds? From 0 to 100%     100  100  100  100  100 

National Immunization Advisory Mechanism

Has the country a standing technical advisory group on immunization (NITAG)? Yes/No/NR No  No  No  No  Yes  No  No 

Sources

 1  "The 2019 World Bank Development Indicators Online", GDP per capita is PPP adjusted.
 2  UN Inter-agency Group for Child Mortality Estimation (https://childmortality.org/data)  
 3  "United Nations, Population Division. The World Population Prospects - the 2019 revision". New York, 2019.
 4  UNICEF/WHO survey database
 5  If no official estimate is available, the administrative coverage is reported. '*' indicates coverage over 99.5%.
 6  WHO-UNICEF estimates.